FUKOKU MUTUAL LIFE INSURANCE Co Boosts Holdings in Boston Scientific Co. (NYSE:BSX)

FUKOKU MUTUAL LIFE INSURANCE Co grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 47.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,725 shares of the medical equipment provider’s stock after buying an additional 3,130 shares during the quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Boston Scientific were worth $815,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC boosted its holdings in shares of Boston Scientific by 3.2% during the third quarter. OneDigital Investment Advisors LLC now owns 10,177 shares of the medical equipment provider’s stock valued at $853,000 after acquiring an additional 311 shares during the period. Lifeworks Advisors LLC grew its stake in shares of Boston Scientific by 48.3% in the third quarter. Lifeworks Advisors LLC now owns 4,653 shares of the medical equipment provider’s stock worth $390,000 after purchasing an additional 1,515 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Boston Scientific by 2.4% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 41,885 shares of the medical equipment provider’s stock valued at $3,510,000 after purchasing an additional 998 shares during the period. Metis Global Partners LLC raised its stake in shares of Boston Scientific by 3.9% during the third quarter. Metis Global Partners LLC now owns 59,226 shares of the medical equipment provider’s stock valued at $4,963,000 after purchasing an additional 2,248 shares in the last quarter. Finally, Aubrey Capital Management Ltd lifted its position in Boston Scientific by 3.4% in the third quarter. Aubrey Capital Management Ltd now owns 49,200 shares of the medical equipment provider’s stock worth $4,123,000 after purchasing an additional 1,600 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BSX. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Sanford C. Bernstein boosted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Stifel Nicolaus upped their price target on shares of Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a report on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.39.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the sale, the chief executive officer now owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. The trade was a 9.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now owns 37,468 shares in the company, valued at $3,061,135.60. This represents a 15.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 309,270 shares of company stock worth $26,196,718. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $87.59 on Friday. Boston Scientific Co. has a 12-month low of $53.56 and a 12-month high of $89.30. The company has a market cap of $129.09 billion, a PE ratio of 72.39, a PEG ratio of 2.61 and a beta of 0.79. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The business’s fifty day simple moving average is $85.03 and its 200-day simple moving average is $79.33.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter in the previous year, the company earned $0.50 earnings per share. The company’s quarterly revenue was up 19.3% on a year-over-year basis. Analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.